[Evaluation of clinical effectiveness of intravenous laser irradiation of blood, plasmapheresis and their combination in patients with bronchial asthma]. / Izuchenie klinicheskoi éffektivnosti vnutrivennogo lazernogo oblucheniia krovi, plazmafereza i ikh sochetaniia u bol'nykh bronkhial'noi astmoi.

AIM: To compare clinical response to intravenous laser radiation of blood (ILRB), plasmapheresis (PA) and ILRB + PA in patients with bronchial asthma (BA). MATERIALS AND METHODS: 122 patients with endogenic BA of moderate severity were divided into four groups: group 1 was exposed to ILRB, group 2--to PA, group 3--to ILRB + PA, group 4 received only chemotherapy. The effect was assessed by body plethismography, peak flowmetry, NBT-test, LCP-test. RESULTS: Patients of group 1-3 vs group 4 demonstrated earlier disappearance of cough and normalization of lung auscultative picture, lower demand of oral glucocorticosteroids, 2 times longer remission, better external respiration function, earlier normalization of peak expiration flow. ILRB, PA and ILRB + PA activate function of oxygen-dependent bactericidal system of blood neutrophils and inhibited activity of non-oxygen-dependent system. CONCLUSION: Combined treatment of moderate severity BA with ILRB, PA alone and in combination is more effective than conventional drug therapy, the highest effect by remission terms being achieved in combination of ILRB with PA.

[Complex assessment of inhacort effectiveness in bronchial asthma]. / Kompleksnaia otsenka éffektivnosti ingakorta pri lechenii bol'nykh bronkhial'noi astmoi.

AIM: To investigate efficiency of inhacort in long-term (6 months to 2 years) treatment of bronchial asthma (BA). MATERIALS AND METHODS: 67 inpatients and 65 outpatients with moderate BA were divided into two groups. 96 patients of group 1 had received standard combined treatment without glucocorticosteroids (GCS), 36 patients of group 2 had received GCS. Inpatients were given inhacort in a dose 1000 micrograms/day, outpatients took inhacort in a daily dose 500 micrograms/day. The examination scheme included assessment of external respiration function (ERF), blood hydrocortisone, sputum rheology and diagnosis of candidosis. RESULTS: Inhacort treatment has reduced frequency of asphyxia attacks 2.5-fold 30 and 25% of the patients stopped taking sympathomimetics and GCS, respectively. None of the patients had asphyxia as a status. ERF, sputum viscosity improved, hydrocortisone secretion was unchanged. Only 3.8% of the patients developed oral candidosis. CONCLUSION: Inhacort in a dose 1 mg controls BA. 73% of the patients treated outpatiently had no need in hospitalization.

[Prestarium treatment of essential hypertension]. / Ispol'zovaniie prestariuma u bol'nykh gipertonicheskoi bolezn'iu.

The aim of the study was to assess prestarium effects on central and renal hemodynamics, blood lipids in hypertensive subjects. Prestarium was given in a daily dose 4-6 mg to 30 patients with essential hypertension stage II free of cardiac decompensation and renal failure. Echocardiography, tetrapolar chest rheoplethysmography with assessment of hemodynamics, radionuclide tracing of renal blood flow, tests for cholesterol and blood electrolytes were made before treatment, on treatment weeks 2-3 and 12. It was found that prestarium lowers blood pressure and total peripheral vascular resistance. Myocardial conductivity was not affected, whereas renal circulation activated. Low-density lipoproteins cholesterol fell. No significant changes in electrolytes were seen. The drug was well tolerated. In view of good clinical effect and tolerance prestarium is recommended for treatment of essential hypertension stage II in the absence of cardiac decompensation and renal dysfunction.

[Gopten (trandolapril) in the treatment of chronic heart failure in patients with ischemic heart disease]. / Gopten (trandolapril) pri lechenii khronicheskoi serdechnoi nedostatochnosti u bol'nykh ishemicheskoi bolezn'iu serdtsa.

AIM: To investigate clinical efficacy of angiotensin-converting enzyme inhibitor trandolapril and its effects on myocardial function. MATERIALS AND METHOD: 20 patients with ischemic heart disease (IHD) aged 33-74 years with chronic cardiac failure NYHA class II-IV. 4 of them survived myocardial infarction. In addition to the routine tests, the patients underwent echocardiography, radionuclide ventriculography. Trandolapril was given once a day for 28 days in a dose 2 mg, then a repeat examination was performed. RESULTS: Trandolapril produced a subjective effect in 80% of patients. There was also improvement of hemodynamic parameters, an increase in the ejection fraction, sensitivity to nitroglycerin, decline of asynchrony. The drug was well tolerated. CONCLUSION: Trandolapril (Gopten) is effective in IHD patients with chronic cardiac failure.

[A complex evaluation of the efficacy of aldecin in treating bronchial asthma patients]. / Kompleksnaia otsenka éffektivnosti al'detsina pri lechenii bol'nykh bronkhial'noi astmoi.

AIM: Study of efficiency of inhalation glucocorticosteroid Aldecine. MATERIALS AND METHODS: A 4-week trial of 30 patients with bronchial asthma. Treatment results were evaluated by clinical symptoms, demand of inhalation sympathomimetics, external respiration, viscosity and elasticity of bronchial secretion, concentrations of hydrocortisone and thyroid hormones. RESULTS: Aldecine produced a good clinical effect, improved external respiration, allowed to reduce doses of inhalation beta-adrenomimetics. No deterioration of either bronchial secretion rheology or inhibition of adrenal and thyroid function was seen. Candidiasis was clinically negligible. CONCLUSION: Aldecine proved highly effective and tolerable in patients with bronchial asthma.

[The effect of salben on the rheological properties of the bronchial secretion]. / Vliianie sal'bena na reologicheskie svoistva bronkhial'nogo sekreta.

AIM: Assessment of the effect of a new Russian selective sympathomimetic salben (powder for inhalations) on bronchial secretion viscosity and adhesion. MATERIALS AND METHODS: Salben or placebo (sodium bensoate) were given to 82 and 30 patients (control) with bronchial asthma, respectively. The response was assessed by clinical, laboratory and instrumental findings. RESULTS: A statistically significant (p < 0.05) reduction of the viscosity and adhesion (by 15 and 20%, respectively) was noted in the salben group which also demonstrated improved external respiration. CONCLUSION: Salben induced positive effect on bronchial secretion viscosity and adhesion.

[The possibilities of isoptin treatment of pulmonary hypertension in patients with chronic obstructive bronchitis]. / Vozmozhnosti lecheniia izoptinov legochnoi gipertenzii u bol'nykh khronicheskim obstruktivnym bronkhitom.

The study included 30 patients with COB coursing from 5 to 15 years, free of chronic cor pulmonale symptoms. All the patients had moderate obstructive impairment of pulmonary ventilation with hemodynamic disorders and defects in myocardial contractility indicating the presence of transitory pulmonary hypertension (PH). Patients of the control group received conventional therapy. It was combined with isoptin-retard (240 mg/day) in the study group. The treatment produced a positive effect in all the patients, but those of the study group exhibited more pronounced decrease in pulmonary artery pressure, achieved better hemodynamics and myocardial contractility. Isoptin-retard in daily dose 240 mg is recommended in COB patients to prevent onset of chronic cor pulmonale.

[Clinical trial of the effects of isodibut on several indicators of microcirculation in combined therapy of patients with diabetes mellitus]. / Klinicheskaia otsenka vliianiia izodibuta na nekotorye pokazateli mikrotsirkuliatsii v kompleksnom terapii bol'nykh sakharnym diabetom.

The authors have tried a new drug isodibut, aldoreductase inhibitor, of Russian produce in 53 patients with diabetes mellitus. A course of isodibut++ has improved blood coagulation and fibrinolysis, microcirculatory blood flow, normalized muscular blood flow as indicated by electrocoagulation, conjunctival biomicroscopy, radionuclide tracing. The drug is recommended for treatment and prevention of diabetic angiopathy.

[Beclomethasone dipropionate, budesonide and flunisolide in the treatment of bronchial asthma (a review of the literature and the authors' own research)]. / Beklometazona dipropionat, budesonid i flunizolid v lechenii bronkhial'noi astmy (obzor literatury i sobstvennye issledovaniia).

Inhalation corticosteroids (beclometasone dipropionate, budesonide, flunisolide) proved effective against bronchial asthma (BA) and safe as they induce no severe systemic side effects. Of these three drugs side effects arise most frequently in administration of beclometasone dipropionate, least frequently of flunisolide. These inhalation corticosteroids are indicated both in non-steroid-dependent and steroid-dependent BA to reduce the dose of oral steroids or, if possible, for their complete discontinuation. Flunisolide is the most potent and effective of all inhalation corticosteroids used in current practice.

[Evaluation of the hormonal status of patients with bronchial asthma by using various drug doses]. / Otsenka gormonal'nogo statusa u bol'nykh bronkhial'noi astmoi pri razlichnykh farmakologicheskikh nagruzkakh.

Drug loads were used to diagnose impairments of the hypothalamic-pituitary-adrenal system in 209 patients with bronchial asthma. A thyroid-releasing hormone test made in patients with moderate bronchial asthma who were taking no corticosteroids (CS) demonstrated a high level of thyroid-stimulating hormone at min 60 of the agent administration, which was indicative of decreased hypothalamic function. In 67.8% of patients, the vasopressin test was positive and suggested that the pituitary preserved its functional capacities. The decreased secretion of hydrocortisone and its active forms was observed in patients with severe bronchial asthma when CS was used in the daily dose adequate to 10-15 mg of prednisolone for 5 years. The 20-day therapy with dexamethasone demonstrated that the agent reduced the synthesis of hydrocortisone to a greater extent than that of corticosterone. The administration of depot-synacthen 24 hours later elevated the content of all hydrocortisone fractions and biologically active corticosterone. Depot-synacthen exerted an active stimulating action on the adrenal cortex.

[Hemodynamic changes in patients with large postoperative ventral hernias]. / Izmeneniia gemodinamicheskikh pokazatelei u bolnykh s bolshimi posleoperatsionnymi ventralnymi gryzhami.

Hemodynamic parameters have been analyzed in 68 inpatients with large postoperative ventral hernia. Most of the patients showed normodynamic circulation. The artificial rise of the intra-abdominal pressure in the course of the preoperative preparation induced hypodynamic response of the cardiovascular system. Early after the surgery, the patients had hypodynamic circulation. As compared to induced abdominal hypertension, this hypodynamia was less pronounced indicating adaptation of the cardiac activity to preoperative hypertension. This is confirmed by the absence of complications related to high intraabdominal pressure in early postoperative period.

[A comparative evaluation of the effect of glurenorm and sulfonylurea preparations on the intravascular microcirculatory indices in type-II diabetes mellitus]. / Sravnitel'naia otsenka vliianiia gliurenorma i nekotorykh preparatov sul'fonilmocheviny na pokazateli vnutrisosudistoi mikrotsirkuliatsii pri sakharnom diabete II tipa.

Analysis of the effects of glurenorm and some sulfonylurea drugs, such as maninil, minidiab, chlorpropamide, on some parameters of intravascular microcirculation has demonstrated the specific features of this drug. Though all these hypoglycemic agents favorably influence the microcirculation when carbohydrate metabolism compensation is attained, glurenorm improved the status of formed elements of the blood (red cell and platelet aggregation) more noticeably than the rest drugs, which fact recommends it as a drug of choice for patients with type II medium-severe diabetes with the predominant involvement of the cellular component of the microcirculation.